Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Cheryl Galt who wrote (30128)	1/11/2000 4:38:00 PM
From: J Stone	Read Replies (2) \| Respond to of 32384

My question is: If results from two arms of the Targretin ABC study are known and the results were strongly positive, would LGND need to wait for completion of the 3rd arm before announcing results? If not, then we might infer that LGND's lack of reporting on study results indicates weak results. Hope I'm wrong. All comments welcome. Jeff

To: Cheryl Galt who wrote (30128)	1/11/2000 8:44:00 PM
From: Mudcat	Read Replies (1) \| Respond to of 32384

3 arms of ABC Based on Cheryl's posting of the 3 arms: I. Compare the efficacy of oral bexarotene (LGD1069) at two different dose levels [200 and 500 mg/?] in patients with advanced breast cancer. II. Assess the safety and tolerability of this treatment regimen in this patient population. III. Evaluate the efficacy of oral bexarotene in terms of induction of differentiation and decreased aberrant cell proliferation in these patients. Arm 1 compares results using two doses of Targretin alone. Arm 2 accesses the safety and side effects If Robert is correct, Targretin alone didn't produce good results when used alone at either dosage in Arm 1. Arm 2 most likely produced the same side effects that we saw previously in the other studies. (increased tryglicerides, headache, etc.) Arm 3 will be the test to see if Targretin increases the effectiveness of Tamoxifen when used in combination with Targretin. Lgnd doesn't want the results of the first two phases released because they were not good and Lgnd most likely knew all along that using Targretin in combination with Tamoxifen was the only way they would get positve test results. They want all 3 released at the same time so the last phase, hopefully, offsets the poor results in the first two arms. All of this is just my speculation of course. I am not sure why they are having trouble getting people for Arm 3 if they were able to get enough for Arm 1. Seems to me Arm 1 would harder to get patients for.